Cellectis: Monthly Information on Share Capital and Company Voting Rights
July 06 2018 - 4:30PM
Business Wire
(Article 223-16 of General Regulation of the
French financial markets authority)
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS):
Listing market: NYSE Euronext Paris
ISIN code: FR0010425595
Date Total number of shares
in the capital
Total number of
votingrights
06/30/2018 42,406,368 42,928,431
About CellectisCellectis is a clinical-stage
biopharmaceutical company focused on developing a new generation of
cancer immunotherapies based on gene-edited T-cells (UCART). By
capitalizing on its 18 years of expertise in gene editing – built
on its flagship TALEN® technology and pioneering electroporation
system PulseAgile – Cellectis uses the power of the immune system
to target and eradicate cancer cells.
Using its life-science-focused, pioneering genome engineering
technologies, Cellectis’ goal is to create innovative products in
multiple fields and with various target markets.Cellectis is listed
on the Nasdaq market (ticker: CLLS) and on Euronext Growth (ticker:
ALCLS). To find out more about us, visit our website:
www.cellectis.com
Talking about gene editing? We do it. TALEN® is a registered
trademark owned by the Cellectis Group.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180706005156/en/
CellectisMedia contacts:Jennifer Moore,
917-580-1088VP of Communicationsmedia@cellectis.comorCaitlin
Kasunich, 212-896-1241KCSA Strategic
Communicationsckasunich@kcsa.comorIR contact:Simon Harnest,
646-385-9008VP of Corporate Strategy and
Financesimon.harnest@cellectis.com
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Sep 2023 to Sep 2024
